Literature DB >> 26788753

Chronic Normobaric Hypoxia Induces Pulmonary Hypertension in Rats: Role of NF-κB.

Junming Fan1, Xiaofang Fan1, Yang Li1, Lu Ding1, Qingqing Zheng1, Jinbin Guo1, Dongmei Xia1, Feng Xue1, Yongyu Wang1, Shufang Liu2, Yongsheng Gong1.   

Abstract

To investigate whether nuclear factor-kappa B (NF-κB) activation is involved in chronic normobaric hypoxia-induced pulmonary hypertension (PH), rats were treated with saline or an NF-κB inhibitor, pyrrolidine dithiocarbamate (PDTC, 150 mg/kg, sc, twice daily), and exposed to normoxia or chronic normobaric hypoxia with a fraction of inspired oxygen of ∼0.1 for 14 days. Lung tissue levels of NF-κB activity, and interleukin (IL)-1β, IL-6, and cyclooxygenase-2 mRNAs, were determined, and mean pulmonary arterial pressure, right ventricular hypertrophy, and right heart function were evaluated. Compared to the normoxia exposure group, rats exposed to chronic normobaric hypoxia showed an increased NF-κB activity, measured by increased nuclear translocation of p50 and p65 proteins, an increased inflammatory gene expression in the lungs, elevated mean pulmonary arterial blood pressure and mean right ventricular pressure, right ventricular hypertrophy, as assessed by right ventricle-to-left ventricle plus septum weight ratio, and right heart dysfunction. Treatment of hypoxia-exposed rats with PDTC inhibited NF-κB activity, decreased pulmonary arterial blood pressure and right ventricular pressure, and ameliorated right ventricular hypertrophy and right heart dysfunction. Hypoxia exposure increased protein kinase C activity and promoted pulmonary artery smooth muscle cell proliferation in vitro. Our data suggest that NF-κB activation may contribute to chronic normobaric hypoxia-induced PH.

Entities:  

Keywords:  hypoxia; inflammation; nuclear factor-kappa B; pulmonary artery smooth muscle cells; pulmonary hypertension

Mesh:

Substances:

Year:  2016        PMID: 26788753     DOI: 10.1089/ham.2015.0086

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  11 in total

Review 1.  Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature.

Authors:  Gerald J Maarman; Rainer Schulz; Karen Sliwa; Ralph Theo Schermuly; Sandrine Lecour
Journal:  Br J Pharmacol       Date:  2017-02-24       Impact factor: 8.739

2.  Crosstalk between the Akt/mTORC1 and NF-κB signaling pathways promotes hypoxia-induced pulmonary hypertension by increasing DPP4 expression in PASMCs.

Authors:  Ying Li; Li Yang; Liang Dong; Zhi-Wei Yang; Jing Zhang; Sheng-Li Zhang; Meng-Jie Niu; Jing-Wen Xia; Yi Gong; Ning Zhu; Xiu-Juan Zhang; Yuan-Yuan Zhang; Xiao-Min Wei; You-Zhi Zhang; Peng Zhang; Sheng-Qing Li
Journal:  Acta Pharmacol Sin       Date:  2019-07-17       Impact factor: 6.150

Review 3.  Redox Regulation, Oxidative Stress, and Inflammation in Group 3 Pulmonary Hypertension.

Authors:  Olena Rudyk; Philip I Aaronson
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  PPARγ attenuates hypoxia-induced hypertrophic transcriptional pathways in the heart.

Authors:  Abubakr Chaudhry; Kristal A Carthan; Bum-Yong Kang; John Calvert; Roy L Sutliff; C Michael Hart
Journal:  Pulm Circ       Date:  2017-03-13       Impact factor: 3.017

5.  Rieske iron-sulfur protein induces FKBP12.6/RyR2 complex remodeling and subsequent pulmonary hypertension through NF-κB/cyclin D1 pathway.

Authors:  Lin Mei; Yun-Min Zheng; Tengyao Song; Vishal R Yadav; Leroy C Joseph; Lillian Truong; Sharath Kandhi; Margarida M Barroso; Hiroshi Takeshima; Marc A Judson; Yong-Xiao Wang
Journal:  Nat Commun       Date:  2020-07-15       Impact factor: 14.919

6.  CYP2J2 and EETs protect against pulmonary arterial hypertension with lung ischemia-reperfusion injury in vivo and in vitro.

Authors:  Yun Ding; Pengjie Tu; Yiyong Chen; Yangyun Huang; Xiaojie Pan; Wenshu Chen
Journal:  Respir Res       Date:  2021-11-13

Review 7.  Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Jaylen Hudson; Laszlo Farkas
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

Review 8.  Hypoxia and the integrated stress response promote pulmonary hypertension and preeclampsia: Implications in drug development.

Authors:  Xiang-Qun Hu; Lubo Zhang
Journal:  Drug Discov Today       Date:  2021-07-22       Impact factor: 7.851

Review 9.  Technical Feasibility and Physiological Relevance of Hypoxic Cell Culture Models.

Authors:  Jiri Pavlacky; Jan Polak
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-21       Impact factor: 5.555

10.  Upregulation of miR-335-3p by NF-κB Transcriptional Regulation Contributes to the Induction of Pulmonary Arterial Hypertension via APJ during Hypoxia.

Authors:  Junming Fan; Xiaofang Fan; Hui Guang; Xiaoqiong Shan; Qiuyun Tian; Fukun Zhang; Ran Chen; Fangzhou Ye; Hui Quan; Haizeng Zhang; Lu Ding; Zhuohui Gan; Feng Xue; Yongyu Wang; Sunzhong Mao; Lianggang Hu; Yongsheng Gong
Journal:  Int J Biol Sci       Date:  2020-01-01       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.